SCHEMBL13469239

SCHEMBL13469239

CCc1ccc(OC)cc1C(=O)O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.57
POLB P06746 6/20 0.53
KDM4E B2RXH2 5/20 0.53
AKR1C3 P42330 4/20 0.49
AKR1C2 P52895 4/20 0.49
ALDH1A1 P00352 4/20 0.49
HSD17B10 Q99714 3/20 0.49
RAB9A P51151 2/20 0.48
HPGD P15428 2/20 0.48
TSHR P16473 1/20 0.48
LMNA P02545 2/20 0.48
TDP1 Q9NUW8 2/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
NPC1 O15118 1/20 0.48
APEX1 P27695 1/20 0.48
MEN1 O00255 1/20 0.48
MAPT P10636 1/20 0.48
KMT2A Q03164 1/20 0.48
CA1 P00915 2/20 0.47
CA2 P00918 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8482547 0.87 SMN1; SMN2 (0.56) SMN1; SMN2POLBKDM4EAKR1C3AKR1C2
SCHEMBL8482552 0.87 SMN1; SMN2 (0.60) SMN1; SMN2POLBKDM4EAKR1C3AKR1C2
SCHEMBL28032582 0.87 POLB (0.47) SMN1; SMN2POLBKDM4EAKR1C3ALDH1A1
SCHEMBL18280327 0.86 SMN1; SMN2 (0.54) SMN1; SMN2POLBKDM4EAKR1C3AKR1C2
SCHEMBL8338550 0.86 SMN1; SMN2 (0.54) SMN1; SMN2POLBKDM4EAKR1C3AKR1C2
SCHEMBL1399960 0.86 HSD17B10 (0.63) SMN1; SMN2POLBKDM4EAKR1C3AKR1C2
SCHEMBL7073236 0.86 SMN1; SMN2 (0.54) SMN1; SMN2POLBKDM4EAKR1C3AKR1C2
SCHEMBL27480514 0.86 SMN1; SMN2 (0.54) SMN1; SMN2POLBKDM4EAKR1C3AKR1C2
SCHEMBL12328328 0.85 KDM4E (0.50) SMN1; SMN2POLBKDM4EALDH1A1HSD17B10
SCHEMBL687106 0.85 KDM4E (0.53) SMN1; SMN2POLBKDM4EAKR1C3AKR1C2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3393467-B1 COMPOSITIONS COMPRISING NICOTINAMIDE RIBOSIDE AND A UROLITHIN AMAZENTIS SA (CH) 2020-07-01 EP disclosed
US-10421720-B2 Octahydrocyclopentapyrroles, their preparation and use THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2019-09-24 US disclosed
WO-2017109195-A1 COMPOSITIONS COMPRISING NICOTINAMIDE RIBOSIDE AND A UROLITHIN AMAZENTIS SA (CH) 2017-06-29 WO disclosed
CN-106414430-A Pharmacologically active quinazolinedione derivatives 奥赖恩公司 2017-02-15 CN disclosed
WO-2016008862-A1 SUBSTITUTED VINYL AND ALKYNYL CYANOCYCLOALKANOLS AND VINYL AND ALKYNYL CYANOHETEROCYCLOALKANOLS AS ACTIVE AGENTS AGAINST ABIOTIC PLANT STRESS BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) 2016-01-21 WO disclosed
WO-2012139891-A1 SUBSTITUTED VINYL AND ALKINYL CYCLOHEXENOLS AS ACTIVE AGENTS AGAINST ABIOTIC STRESS IN PLANTS BAYER CROPSCIENCE AG (DE) 2012-10-18 WO disclosed
US-7446195-B2 High affinity thiophene-based and furan-based kinase ligands SCHERING CORPORATION (US) 2008-11-04 US disclosed
US-20070043045-A1 Novel high affinity thiophene-based and furan-based kinase ligands SCHERING CORPORATION 2007-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10421720-B2 Octahydrocyclopentapyrroles, their preparation and use CLN6, ALDH1A2, C1S SMN1; SMN2 1454/4885POLB 1395/4885KDM4E 4528/4885
US-20070043045-A1 Novel high affinity thiophene-based and furan-based kinase ligands CDKL2, CDK2, CDKL1 SMN1; SMN2 2211/4885POLB 1045/4885KDM4E 638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.